Piramal Pharma Solutions
India Updated 9 July 2026
The public registers hold a second record for Piramal Pharma Solutions. The fuller profile,
with 62 active US DMFs and 29 valid CEPs, is at Piramal Pharma.
Figures on this page cover only this record.
Piramal Pharma Solutions is a finished-dose manufacturer based in India. It appears in 1 regulatory filing across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 10 December 2025 as VAI.
2
registered plants
1 with an FDA FEI number
1
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Inspection history
- 10 December 2025 VAI US FDA
- 10 January 2023 VAI US FDA
- 11 April 2019 NAI US FDA
- 14 March 2018 VAI US FDA
- 17 April 2014 VAI US FDA
- 15 April 2014 NAI US FDA
- 27 February 2009 VAI US FDA
- 13 February 2009 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Leiden, Netherlands | Not on file |
| Lexington, United States | 3006419237 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| MINSA (CR) | 1 | None |
| EMA | None | 1 |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Piramal Pharma Solutions comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 10 December 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates